替吉奥联合紫杉醇治疗晚期胃癌的疗效观察

Efficacy of S-1 Combined with Paclitaxel for Patients with Advanced Gastric Cancer

目的探讨替吉奥联合紫杉醇治疗晚期胃癌的疗效及不良反应。方法将92例胃癌晚期患者依据治疗方法分为替吉奥联合紫杉醇治疗组(观察组)和传统常规治疗组(对照组)。比较2组治疗的临床疗效和不良反应情况。结果观察组有效率为52.17%(24/46),对照组有效率为43.48%,2组差异具有统计学意义(P<0.05)。观察组患者在治疗过程中产生的不良反应少于对照组,差异具有统计学意义(P<0.05)。结论替吉奥联合紫杉醇治疗晚期胃癌的疗效相对明显,且产生的毒副作用明显少于传统治疗方法。

Objective To investigate the efficacy and adverse reactions of S-1 combined with paclitaxel for patients with advanced gastric cancer. Methods 92 patients with advanced gastric cancer patients,according to treatment methods,were divided into S-1 plus paclitaxel group( observation group) and traditional conventional treatment group( control group). Clinical efficacy and adverse reactions of the 2 groups were compared. Results The effective rate in the observation group was 52. 17%( 24 /46),and that of the control group was 43. 48%,there had statistically significant difference between the 2 groups( P <0. 05). Adverse reactions in the observation group was less than that of the control group,the difference was statistically significant( P < 0. 05). Conclusion S-1 combined with paclitaxel for advanced gastric cancer is effective,and the side effects is less than traditional treatment methods.